Cefdinir

Cefdinir

Clinical data
Pregnancy category	US: B (No risk in non-human studies)
Routes of administration	Oral
ATC code	J01DD15 (WHO)
Legal status
Legal status	US: ℞-only
Pharmacokinetic data
Bioavailability	16% to 21% (dose-dependent)
Protein binding	60% to 70%
Metabolism	Negligible
Elimination half-life	1.7 ± 0.6 hours
Excretion	Renal
Identifiers
IUPAC name 8-[2-(2-amino-1,3-thiazol-4-yl)-1-hydroxy-2-nitroso- ethenyl]amino-4-ethenyl-7-oxo-2-thia-6- azabicyclo[4.2.0]oct-4-ene-5-carboxylic acid
CAS Number	91832-40-5
PubChem CID	6399253
DrugBank	APRD00644
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C14H13N5O5S2
Molar mass	395.416 g/mol

WikiDoc Resources for Cefdinir
Articles
Most recent articles on Cefdinir Most cited articles on Cefdinir Review articles on Cefdinir Articles on Cefdinir in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Cefdinir Images of Cefdinir Photos of Cefdinir Podcasts & MP3s on Cefdinir Videos on Cefdinir
Evidence Based Medicine
Cochrane Collaboration on Cefdinir Bandolier on Cefdinir TRIP on Cefdinir
Clinical Trials
Ongoing Trials on Cefdinir at Clinical Trials.gov Trial results on Cefdinir Clinical Trials on Cefdinir at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Cefdinir NICE Guidance on Cefdinir NHS PRODIGY Guidance FDA on Cefdinir CDC on Cefdinir
Books
Books on Cefdinir
News
Cefdinir in the news Be alerted to news on Cefdinir News trends on Cefdinir
Commentary
Blogs on Cefdinir
Definitions
Definitions of Cefdinir
Patient Resources / Community
Patient resources on Cefdinir Discussion groups on Cefdinir Patient Handouts on Cefdinir Directions to Hospitals Treating Cefdinir Risk calculators and risk factors for Cefdinir
Healthcare Provider Resources
Symptoms of Cefdinir Causes & Risk Factors for Cefdinir Diagnostic studies for Cefdinir Treatment of Cefdinir
Continuing Medical Education (CME)
CME Programs on Cefdinir
International
Cefdinir en Espanol Cefdinir en Francais
Business
Cefdinir in the Marketplace Patents on Cefdinir
Experimental / Informatics
List of terms related to Cefdinir

Cefdinir (marketed by Abbott Laboratories under the brand name Omnicef) is a semi-synthetic, broad-spectrum antibiotic in the third generation of the cephalosporin class, proven effective for common bacterial infections of the ear, sinus, throat, and skin. It was approved by the U.S. Food and Drug Administration (FDA) in December of 1997.

Mechanism of action

Main article: Cephalosporin

Indications

Therapeutic uses of cefdinir include otitis media, soft tissue infections, and respiratory tract infections, including sinusitis, strep throat, community-acquired pneumonia and acute exacerbations of bronchitis.

Susceptible organisms

Cefdinir is a bacteriocidal antibiotic. It can be used to treat infections caused by several Gram-negative and Gram-positive bacteria, including:

Gram-negative

• Haemophilus influenzae
• Moraxella catarrhalis
• Escherichia coli
• Klebsiella spp.
• Proteus mirabilis

Gram-positive

• Staphylococcus aureus
• Streptococcus pneumoniae
• Streptococcus pyogenes

Like most third-generation cephalosporins (except Ceftazidime), cefdinir is not an effective treatment against infections caused by Pseudomonas aeruginosa.

Side effects

According to the Omnicef website, side effects include "(...) diarrhea, vaginal infections or inflammation, nausea, headache, and abdominal pain."

Available forms and dosage

File:Omnicef300mg.jpg

Omnicef 300 mg

Cefdinir is administered orally. It is available as capsules and a suspension. Dosage, schedule, and duration of therapy varies according to the type of infection. For adults, the average dosage is between 300 and 600 mg per 12 or 24 hour period, for the duration of between 5 and 10 days. Average pediatric dosage is between 7 and 14 mg/kg (schedule and duration the same as adult).

Notes

• Marketed by Hikma Pharmaceuticals PLC in MENA region under the brand name Omnicef®

"Blood" in the Stool

The pediatric version of Omnicef® can bind to iron in the digestive tract. In rare cases, this creates a discoloration of the stool to a rust or red color. Some patients may interpret this as blood in the stool, although in reality blood appears dark brown or black in the stool. A doctor's office can perform a simple stool guaiac test on the stool to confirm that it does not have blood. If you simply wait one hour, the red color will remain red, (while real blood will turn black).

On the other hand, if the reddish stool is accompanied by abdominal pain, weight loss, diarrhea, etc., it could be a C. difficile (clostridium difficile) infection caused by the antibiotic. This infection can occur as a result of taking an antibiotic. Talk to your pediatrician immediately to see if you should stop using the antibiotic.

External links

• Omnicef homepage